BRD2 Antibody (BL-167-2A2)

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-76410

Recombinant Monoclonal Antibody.
Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP2-76410
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Validated by

Independent Antibodies

Species Reactivity

Validated:

Human, Mouse

Applications

Flow Cytometry, Immunoprecipitation, Western Blot

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Rabbit IgG Clone # BL-167-2A2

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all BRD2 Antibodies »

Product Summary for BRD2 Antibody (BL-167-2A2)

Immunogen

Immunogen sequence between amino acids 675 and 725

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for BRD2 Antibody (BL-167-2A2)

Western Blot: BRD2 Antibody (BL-167-2A2) [NBP2-76410]

Western Blot: BRD2 Antibody (BL-167-2A2) [NBP2-76410]

Western Blot: BRD2 Antibody (BL-167-2A2) [NBP2-76410] - Whole cell lysate (50 ug) from RenCa, NIH 3T3, and C2C12cells prepared using NETN lysis buffer. Antibody: Rabbitanti-BRD2 recombinant monoclonal antibody [BL-167-2A2] used at 1:1000. Secondary: HRP-conjugated goat anti-rabbit IgG. Chemiluminescence with an exposure time of 3 minutes.
Western Blot: BRD2 Antibody (BL-167-2A2) [NBP2-76410]

Western Blot: BRD2 Antibody (BL-167-2A2) [NBP2-76410]

Western Blot: BRD2 Antibody (BL-167-2A2) [NBP2-76410] - Whole cell lysate (50 ug) from HEK293T, MCF-7, Hep-G2,A-549, SW620, SK-MEL-28, and Jurkat cells preparedusing NETN lysis buffer. Antibody: Rabbit anti-BRD2recombinant monoclonal antibody [BL-167-2A2] used at 1:1000. Secondary: HRPconjugatedgoat anti-rabbit IgG Chemiluminescence with an exposure time of 30 seconds.Lower Panel: Rabbit anti-Actin.
Immunoprecipitation: BRD2 Antibody (BL-167-2A2) [NBP2-76410]

Immunoprecipitation: BRD2 Antibody (BL-167-2A2) [NBP2-76410]

Immunoprecipitation: BRD2 Antibody (BL-167-2A2) [NBP2-76410] - Detection of human BRD2 by WB of immunoprecipitates from HEK293T lysate. Antibodies: Rabbit anti-BRD2 recombinant monoclonal [BL-167-2A2] (NBP2-76410) and another rabbit anti-BRD2 antibody.

Applications for BRD2 Antibody (BL-167-2A2)

Application
Recommended Usage

Immunoprecipitation

20 ul/1mg lysate

Western Blot

1:1000
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Formulation

Borate Buffered Saline (BBS) pH 8.2 with 0.1% BSA

Preservative

0.09% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 2 - 8 C / 1 year from date of receipt

Background: BRD2

BRD2 (bromodomain-containing 2) is a nuclear mitogen-activated kinase that plays a role in transcription of cell-cycle-regulated genes (1). Alternate names for BRD2 include RING3, NAT, RNF3, FSRG1, D6S113E, FLJ31942, DKFZp686N0336, and KIAA9001 (2). BRD2 belongs to the BET (bromodomain/extra terminal domain) family of proteins which contain two tandem bromodomains (BDI and BDII) and an extra-terminal (ET) domain (1, 3). In mammals there are four BET paralogs (BRD2, BRD3, BRD4, and BRDT) which have a similar amino acid sequence, domain organization, and function (3). The bromodomain of BRD2 is a ~110 amino acids conserved sequence that forms 4 alpha-helices (alphaZ, alphaA, alphaB, and alphaC) and 2 loops (ZA and BC) that can bind to the acetylated lysine-12 residue of chromatin histone H4 and is required for epigenetic regulation of gene transcription (1-3). The ET is a conserved region of ~80 amino acids that recruits specific effector proteins (3). The theoretical molecular weight of BRD2 is 88 kDa but the observed band is typically ~110 kDa due to post-translational modifications. The coding region of the Brd2 gene contains 11 exons and covers over 6 kb of DNA (3). Furthermore, the gene maps to the major histocompatibility complex (MHC) class II region on chromosome 6p21.3 (2).

BRD2 and the other BET proteins have been implicated in a variety of diseases and pathologies. The BET proteins are known drivers of cancer through mutation and over-expression (1). Recently, in studies examining the role of Type 2 diabetes and obesity in breast cancer progression, the BET proteins have been shown to be critical regulators of metabolism and metastasis and are co-activators for the transcription of genes that encode pro-inflammatory cytokines in immune cells infiltrating the breast cancer microenvironment (1). Accordingly, knockdown of Brd2 in mice protected the animals from developing Type 2 diabetes and stopped the inflammatory response typically elicited by obesity (4). BRD2 is also highly expressed in the brain and the gene has been shown to play a role in juvenile myoclonic epilepsy, a common form of epilepsy that typically reveals itself during adolescence (5). In addition to the brain, BRD2 is highly expressed in the bone marrow and consequently its kinase activity has been shown to increase upon cellular proliferation and is significantly elevated in the peripheral blood lymphocytes of lymphoma patients (2, 3).

Research has been done to better understand protein interactions with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of the novel coronavirus disease 2019 (COVID-19), as possible targets for drug therapies. It was recently described that that the transmembrane envelope protein (E) of SARS-CoV-2 binds to both BRD2 and BRD4, suggesting that bromodomain inhibitors could be a potential drug target (6). More specifically, the bromodomain inhibitors could be relevant regarding the secondary immune-related consequences that arise from SARS-CoV-2 infection (6). Bromodomain inhibitors are currently the focus of multiple clinical trials as a potential therapeutic in cancer and pulmonary arterial hypertension (6).

References

1. Andrieu, G.P., Shafran, J.S., Deeney, J.T., Bharadwaj, K.R., Rangarajan, A., & Denis, G.V. (2018). BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment. J Leukoc Biol. https://doi:10.1002/JLB.5RI0917-380RR

2. BRD2 bromodomain 2 (human), NCBI

3. Taniguchi, Y. (2016). The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. Int J Mol Sci. https://doi:10.3390/ijms17111849

4. Wang, F., Deeney, J.T., & Denis, G.V. (2013). Brd2 gene disruption causes "metabolically healthy" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes. Vitam Horm. https://doi:10.1016/B978-0-12-407766-9.00003-1

5. Gilsoul, M., Grisar, T., Delgado-Escueta, A.V., de Nijs, L., & Lakaye, B. (2019). Subtle Brain Developmental Abnormalities in the Pathogenesis of Juvenile Myoclonic Epilepsy. Front Cell Neurosci. https://doi:10.3389/fncel.2019.00433

6. Harrison, C. (2020). Drug researchers pursue new lines of attack against COVID-19. Nat Biotechnol. https://doi.org/10.1038/d41587-020-00013-z

Long Name

Bromodomain Containing 2

Alternate Names

FSRG1, RING3, RNF3

Gene Symbol

BRD2

Additional BRD2 Products

Product Documents for BRD2 Antibody (BL-167-2A2)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for BRD2 Antibody (BL-167-2A2)

This Product sold under License from Bethyl Laboratories, Inc.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.